Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* volunteers (men and women) aged 18 years and older.~* Literate and willing to provide written informed consent.~* A signed informed consent.~Exclusion Criteria:~* Available in anamnaze volunteer at any allergic reactions.~* Allergic reactions to chicken proteins, or any preceding vaccination.~* Acute illness with a fever (37.0 C).~* Vaccination against influenza in the 2015/2016 season.~* Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.~* Hypersensitivity after previous administration of any vaccine.~* History of chronic alcohol abuse and/or illegal drug use.~* Any clinically significant abnormal laboratory finding.~* A positive pregnancy test for all women of childbearing potential.~* Administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment.~* Acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives.~* History of leukemia or any other blood or solid organ cancer.~* Receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study.~* Participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study.~* Subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine) (Type: ACTIVE_COMPARATOR): 100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
- Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine) (Type: ACTIVE_COMPARATOR): 100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
- Group #3 (Vaccine VAXIGRIP) (Type: EXPERIMENTAL): 50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP
- Group #4 (Vaccine VAXIGRIP) (Type: EXPERIMENTAL): 50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete